Troxacitabine in leukemia

References

• Mansour TS, Jin H, Wang W, et al. Anti-human immuno-deficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2`-deoxy-3′-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem 1995;38:1–4.
   PubMed Web of Science ®Google Scholar
• Giles FJ. Troxacitabine-based therapy of refractory leukemia. Expert Rev Anticancer Ther 2002;2:261–266.
   PubMedGoogle Scholar
• Balzarini J, Wedgwood O, Kruining J, etal. Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun 1996;225: 363–369.
   PubMed Web of Science ®Google Scholar
• Mar EC, Chu CK, Lin JC. Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus. Antiviral Res 1995;28:1–11.
   PubMed Web of Science ®Google Scholar
• Coates JA, Cammack N, Jenkinson HJ, et al. (−)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992;36:733–739.
   PubMed Web of Science ®Google Scholar
• Grove KL, Guo X, Liu SH, Gao Z, Chu CK, Cheng YC. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res 1995;55:3008–3011.
   PubMed Web of Science ®Google Scholar
• Grove KL, Cheng YC. Uptake and metabolism of the new anticancer compound beta-L-(−)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res 1996;56:4187–4191.
   PubMed Web of Science ®Google Scholar
• Siu LL, Attardo G, Izbicka E, et al. Activity of (−)-2′-deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann Oncol 1998;9:885–891.
   PubMed Web of Science ®Google Scholar
• Kadhim SA, Bowlin TL, Waud WR, et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 1997;57:4803–4810.
   PubMed Web of Science ®Google Scholar
• Gourdeau H, Clarke ML, Ouellet F, et al. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res 2001;61:7217–7224.
   PubMed Web of Science ®Google Scholar
• Gourdeau H, Bibeau L, Ouellet F, Custeau D, Bernier L, Bowlin T. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother Pharmacol 2001;47:236–240.
   PubMed Web of Science ®Google Scholar
• Gourdeau H, Leblond L, Hamelin B, et al. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: Implications for clinical development. Clin Cancer Res 2004;10:7692–7702.
   PubMed Web of Science ®Google Scholar
• Owens JK, Shewach DS, Ullman B, Mitchell BS. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-Iymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 1992;52:2389–2393.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Stephenson J, Jr., Baker SD, et al. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2002;20:96–109.
   Google Scholar
• Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G, Cheng YC. Phosphorylation of pyrimidine deoxynucleoside analog dipho-sphates: Selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem 2002;277:5453–5459.
   PubMed Web of Science ®Google Scholar
• Krishnan P, Gullen EA, Lam W, Dutschman GE, Grill SP, Cheng YC. Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents. j Biol Chem 2003;278:36726–36732.
   PubMed Web of Science ®Google Scholar
• Moore LE, Boudinot FD, Chu CK. Preclinical pharmaco-kinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats. Cancer Chemother Pharmacol 1997;39:532–536.
   PubMed Web of Science ®Google Scholar
• Kukhanova M, Liu SH, Mozzherin D, Lin TS, Chu CK, Cheng YC. L.- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J Biol Chem 1995;270: 23055–23059.
   PubMed Web of Science ®Google Scholar
• Grant S. Ara-C: Cellular and molecular pharmacology. Adv Cancer Res 1998;72:197–233.
   PubMed Web of Science ®Google Scholar
• Weitman S, Marty J, Jolivet j, Locas C, Von Hoff DD. The new dioxolane, (−)-2′-deoxy-3′-oxacytidine (BCH-4556, troxaci-tabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res 2000;6: 1574–1578.
   PubMed Web of Science ®Google Scholar
• Schwartz PM, Haggerty JG, Cheng YC. Beta-L-1,3-dioxo-lane-cytidine: A novel nucleoside that inhibits proliferation and induces differentiation of keratinocytes in vitro. Skin Pharmacol Appl Skin Physiol 1998;11: 207–213.
   PubMedGoogle Scholar
• Rabbani SA, Harakidas P, Bowlin T, Attardo G. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Res 1998;58: 3461–3465.
   PubMed Web of Science ®Google Scholar
• Kim TE, Park SY, Hsu CH, Dutschman GE, Cheng YC. Synergistic antitumor activity of troxacitabine and campto-thecin in selected human cancer cell lines. Mol Pharmacol 2004;66:285–292.
   PubMed Web of Science ®Google Scholar
• Gati WP, Paterson AR, Belch AR, et al. Es nucleoside transporter content of acute leukemia cells: Role in cell sensitivity to cytarabine (araC). Leuk Lymphoma 1998;32: 45–54.
   PubMed Web of Science ®Google Scholar
• Bouffard DY, Jolivet J, Leblond L, et al. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells. Cancer Chemother Pharmacol 2003;52:497–506.
   PubMed Web of Science ®Google Scholar
• Orsolic N, Giles FJ, Gourdeau H, et al. Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: Preclinical evaluation. Br J Haematol 2004;124: 727–738.
   PubMed Web of Science ®Google Scholar
• Belanger K, Moore M, Baker SD, et al. Phase I and pharmacokinetic study of novel L-nucleoside analog troxaci-tabine given as a 30-minute infusion every 21 days. J Clin Oncol 2002;20:2567–2574.
   PubMed Web of Science ®Google Scholar
• Canova A, Yee L, Baker SD. A phase I and pharmacokinetic study of beta-L-dioxalo-cytidine (BCH-4556) administered weekly for 3 weeks every 28 days. Proc Am Soc Clin Oncol 1999;18: 197.
   Google Scholar
• Stephenson J, Baker S, Aylesworth C. A phase I and pharmacokinetic study of BCH-4556, a novel L-nucleoside antimetabolite, on a daily × 5 day every 21-day schedule in patients with solid neoplasms. Ann Oncol 1998;9: 156.
   Web of Science ®Google Scholar
• Giles FJ, Cortes JE, Baker SD, et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 2001;19:762–771.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Garcia-Manero G, Cortes JE, et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. j Clin Oncol 2002;20:656–664.
   PubMed Web of Science ®Google Scholar
• Lee CK, Rowinsky EK, Li J, et al. Population pharmacoki-netics of troxacitabine, a novel dioxolane nucleoside analogue. Clin Cancer Res 2006;12:2158–2165.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Feldman EL Roboz GJ, et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res 2003;27: 1091–1096.
   PubMed Web of Science ®Google Scholar
• Alvarado Y, Kantarjian HM, Cortes JE, Apostolidou E, Bivins C, Giles FJ. Troxacitabine activity in extramedullary myeloid leukemia. Hematology 2002;7:179–185.
   PubMedGoogle Scholar
• Giles FJ, Fader’ S, Thomas DA, et al. Randomized phase 1/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 2003;21:1050–1056.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Kantarjian HM, Cortes JE, et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 200321:1722-1727.
   PubMed Web of Science ®Google Scholar
• Giles F, Garcia-Manero G, O’Brien S, Estey E, Kantarjian H. Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome. Acta Haematol 2002;108:164–167.
   PubMed Web of Science ®Google Scholar
• Roboz GR, Giles FJ, Ritchie EK, et al. Phase PII study of troxacitabine administered by continuous infusion in patients with refractory acute myeloid leukemia. J Clin Oncol 2006.
   Web of Science ®Google Scholar
• Giles F, O’Brien S, Cortes J, et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer 2005;104:547–554.
   PubMed Web of Science ®Google Scholar
• Lopez A, Wallace L, Dorr R. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar—plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999;44: 303–306.
   PubMed Web of Science ®Google Scholar
• Vukelja SJ, Lombardo FA, James WD, Weiss RB. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989;111:688–689.
   PubMed Web of Science ®Google Scholar